文献速递垂体与肾上腺疾病

库欣综合征患者抗凝治疗的临床决策:病例导向框架

Approach to the Patient with Cushing's Syndrome: Use of Anticoagulation Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文通过4例库欣综合征(CS)患者,探讨静脉血栓栓塞(VTE)预防中的灰色地带:何时启动、持续多久、使用何种药物及何时停药。作者综合现有证据与专家实践,建议活动性CS诊断时考虑低分子肝素并持续至术后约3个月生化缓解,不推荐常规使用梯度压力袜。

要点

  • 活动性CS诊断时可考虑启动低分子肝素预防VTE。
  • 预防应覆盖手术期并延续至生化缓解后约3个月。
  • 不推荐常规使用梯度压力袜预防VTE。

核心结论

  • 对活动性CS患者可考虑低分子肝素预防VTE,并持续至术后约3个月生化缓解。
  • 不推荐常规使用梯度压力袜预防VTE。
  • 出血并发症虽不常见,但需个体化评估。

研究设计与样本

  • 本文为病例系列与证据综述,呈现4例CS患者的VTE预防决策场景。

主要发现

  • 病例涵盖活动性CS诊断时启动预防、岩下窦采血围术期管理、经蝶手术后围术期预防及药物控制下停药决策。
  • 基于近期数据,不鼓励常规使用梯度压力袜预防VTE。

关键数值与推荐

  • 活动性CS诊断时考虑低分子肝素,持续至手术并延长至生化缓解后约3个月。
  • 出血并发症需个体化权衡。

临床怎么用

  • 根据CS疾病阶段(活动期、围术期、生化缓解后)个体化制定VTE预防策略。
  • 在生化缓解后特定场景可安全停用预防。

局限性

  • 证据异质性大,需前瞻性研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an increased awareness on the higher hypecoagulability risks in patients with Cushing's syndrome (CS), but management remains controversial. Here, we present 4 illustrative cases of CS that exemplify some "grey areas" on venous thromboembolism (VTE) prevention-when to start, how long to continue, what to use, and when to stop. The cases span the initiation of prophylaxis at diagnosis of active CS, periprocedural management around inferior petrosal sinus sampling, perioperative prophylaxis after transsphenoidal surgery (TSS), and discontinuation decisions in medically controlled disease. We synthesize current evidence and expert practice and recommend considering low-molecular-weight heparin at diagnosis of active CS, continuing through surgery, and extending for approximately 3 months after biochemical remission in selected patients to address the highest-events risk window. Based on recent data, we discourage routine use of graduated compression stockings (GCS) for VTE prevention. Though bleeding complications appear uncommon, they need to be carefully considered on an individualized basis. Finally, scenarios where prophylaxis can be safely discontinued once eucortisolaemia is achieved are outlined. This case-anchored framework translates heterogeneous data into actionable guidance and highlights priorities for prospective evaluation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Isand K, Wass J, Karavitaki N, et al. Approach to the Patient with Cushing's Syndrome: Use of Anticoagulation Therapy. J Clin Endocrinol Metab. 2026. PMID: 41396880. doi:10.1210/clinem/dgaf671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。